R&D Trends

Broad Institute, Bayer Healthcare expand partnership

Wednesday, April 1, 2015 01:01 PM

The Broad Institute of MIT and Harvard has expanded its collaboration with Bayer HealthCare to include cardiovascular genomics and drug discovery. The goal of this new part of the alliance is to leverage insights from human genetics to help create new cardiovascular therapies.

More... »

Quest Diagnostics

BARDA awards $35M contract to BioCryst’s BCX4430

Wednesday, April 1, 2015 12:58 PM

The Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) has awarded Durham, N.C.-headquartered BioCryst Pharmaceuticals a contract for the continued development of BCX4430 as a potential treatment for diseases caused by RNA pathogens, including filoviruses.

More... »


Syndax, Merck to collaborate on immuno-oncology study

Wednesday, April 1, 2015 12:54 PM

Syndax Pharmaceuticals, based in Waltham, Mass., and Merck have entered into a clinical trial collaboration to evaluate the safety and efficacy of combining Syndax’s entinostat, an investigational epigenetic therapy, with Merck’s Keytruda (pembrolizumab), the first anti-PD-1 therapy approved in the U.S. The phase Ib/II study will evaluate this novel combination regimen in patients with either advanced non-small cell lung cancer (NSCLC) or melanoma. The study is expected to begin enrolling patients in the second half of 2015.

More... »

Ziopharm-Intrexon collaborate with Merck Serono

Wednesday, April 1, 2015 12:50 PM

Ziopharm Oncology, a Boston, Mass.-based biotech company, and Intrexon, a synthetic biology provider, have announced their oncology programs will be strengthened through Intrexon's new global collaboration focused exclusively on novel chimeric antigen receptor T-cell (CAR-T) products with Merck Serono, the biopharmaceutical division of Merck. Intrexon will share the economic provisions of this collaboration, including upfront payment, milestones and royalties, equally with Ziopharm.

More... »

Aduro Biotech, Novartis collaborate on immuno-oncology products

Wednesday, April 1, 2015 12:50 PM

Aduro Biotech, a private, clinical-stage immuno-oncology company based in Berkeley, Calif., is collaborating with Novartis for the worldwide research, development and commercialization of novel immuno-oncology products derived from Aduro’s cyclic dinucleotide (CDN) approach to target the STING (Stimulator of Interferon Genes) receptor, that, when activated, is known to initiate broad innate and adaptive tumor-specific immune responses.

More... »

NIH awards $9M to speed development of health technologies

Monday, March 30, 2015 02:13 PM

The NIH has selected three new proof-of-concept hubs to help speed the translation of basic biomedical discoveries into commercial products, such as new drugs, devices and diagnostics, to improve patient care and enhance health. The hubs are part of the NIH-supported Research Evaluation and Commercialization Hubs (REACH) program and will be funded $9 million over three years.

More... »

Ablynx, Merck extend ion channel research collaboration

Friday, March 27, 2015 11:21 AM

Ablynx, a biopharmaceutical company headquartered in Belgium, has extended its initial two-year research collaboration with Merck to develop and commercialize Nanobody candidates directed toward an undisclosed voltage gated ion channel.

More... »

Clinicians, researchers and industry collaborate with the 100,000 Genomes Project

Friday, March 27, 2015 11:12 AM

Genomics England has announced a new collaboration as part of the 100,000 Genomes Project to accelerate the development of new diagnostics and treatments for patients. Ten pharma and biotech companies have come together to create the Genomics Expert Network for Enterprises (GENE) Consortium to oversee a year-long industry trial.

More... »

Biomedical Catalyst to award $59M for new research

Thursday, March 26, 2015 03:00 PM

New treatments, diagnostics and medical technologies are set to benefit from an investment of $47 million through the Biomedical Catalyst (BMC)—a partnership between the Medical Research Council (MRC) and Innovate U.K. This MRC and Innovate U.K. funding will be further boosted by over $12 million of investment leveraged from industry, bringing the total investment for this round to $59 million.

More... »

National Institute of Mental Health issues strategic plan for research

Thursday, March 26, 2015 02:57 PM

The National Institute of Mental Health (NIMH) has issued a new strategic plan for research. Informed by the successes and challenges of recent years, the new plan updates the strategic objectives of its 2008 predecessor with the aim of balancing the need for long-term investments in basic research with urgent mental health needs.

More... »

CWWeekly

March 30

Icon, Carnegie Mellon partner to research ways to improve study patients' understanding of Informed Consent

Veeva launches OpenKey, partner program to unlock difficult access to, restrictions on customer reference data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs